# Xuanzhu Biopharmaceutical

Source: https://onco.cc/companies/xuanzhu-biopharmaceutical/  
OnCo record `xuanzhu-biopharmaceutical` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Xuanzhu Biopharmaceutical is a China-based biotechnology company running 3 late-stage cancer trials of XZP-3287 and XZP-5955 in HR-positive / HER2-negative breast cancer and non-small-cell lung cancer.

## Summary

Xuanzhu Biopharmaceutical, based in Beijing, China, is a biotechnology company. Xuanzhu Biopharmaceutical is a China-based biopharmaceutical company developing drugs for digestive system diseases, oncology and NASH (non-alcoholic fatty liver disease). On ClinicalTrials.gov it is the lead sponsor of 3 recruiting or active phase 2 and phase 3 interventional cancer trials (2 in phase 3), testing XZP-3287 and XZP-5955 in HR-positive / HER2-negative breast cancer and non-small-cell lung cancer. The largest, NCT05257395 (A Study of XZP-3287 in Combination With Letrozole/Anastrozole in Patients With Advanced Breast Cancer), plans to enrol 397 participants (actual). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: Xuanzhu Biopharmaceutical Co., Ltd.
- Tags: ctgov-sponsor
- HQ: Beijing
- Type: biotech
- Website: https://www.xuanzhubio.com

## Sources

- Official website: https://www.xuanzhubio.com
- ClinicalTrials.gov: trials led by Xuanzhu Biopharmaceutical: https://clinicaltrials.gov/search?lead=Xuanzhu%20Biopharmaceutical%20Co.%2C%20Ltd.

## Connected records

- cancers: [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [XZP-3287](https://onco.cc/drugs/xzp-3287/)
- trials: [A Study of XZP-3287 in Combination With Fulvestrant in Patients With Advanced Breast Cancer](https://onco.cc/trials/nct05077449/), [A Study of XZP-3287 in Combination With Letrozole/Anastrozole in Patients With Advanced Breast Cancer](https://onco.cc/trials/nct05257395/), [A Study of XZP-5955 Tablets in Patients With NTRK or ROS1 Fusion Positive Locally Advanced or Metastatic Solid Tumors](https://onco.cc/trials/nct04996121/)

---
JSON: https://onco.cc/api/v1/entities/xuanzhu-biopharmaceutical.json